NEXGEL stock regains Nasdaq compliance after bid-price breach

NEXGEL said on October 27, 2026, that it had regained compliance with Nasdaq’s minimum bid price requirement. The company announced the development in a release carried by Nasdaq.

Listing matter is now closed

According to the release, Nasdaq’s Listing Qualifications Department notified NEXGEL that it had satisfied the minimum bid price requirement under Listing Rule 5550(a)(2). The company said the matter is now closed and that its common stock will continue to be listed and traded on the Nasdaq Capital Market.

NEXGEL had previously disclosed a deficiency notice dated April 22, 2026. Nasdaq said the company had failed to maintain a minimum closing bid price of 1.00 US dollar over 30 consecutive business days. To regain compliance, NEXGEL needed to maintain a closing bid price of at least 1.00 US dollar for 10 consecutive trading days. The company said that condition was achieved on October 23, 2026.

What it means for investors

The announcement removes the specific minimum-bid-price deficiency described in the company’s release and reduces an immediate listing risk for shareholders. It does not, by itself, provide an outlook for revenue, earnings or future share-price performance. Investors still need to assess NEXGEL’s operating results, financing needs and execution in its medical technology and hydrogel businesses separately.

NEXGEL operates through its BIONX Surgical division and also develops healthcare, beauty and over-the-counter hydrogel products. The company is based in Langhorne, Pennsylvania.

For investors tracking the broader US market backdrop, the S&P 500 remains the relevant benchmark context.

More news and analyses on NEXGEL stock